Humana Inc.

(New York Stock Exchange)
Back to all articles
Very Bullish +85

Humana (HUM) Stock Surges as Medicare Ratings Stage Comeback

Regulatory approval AI-generated analysis

πŸ“ˆ Humana stock climbed roughly 15% in premarket trading after announcing improved Medicare Advantage Star Ratings for the 2027 plan year.

⭐ The company reported that 95% of its Medicare Advantage members are now enrolled in four-star or higher plans, up from just 20% a year ago.

πŸ† Six Medicare Advantage contracts received 4.5-star ratings and twelve received four-star ratings for the upcoming enrollment period.

πŸ’Š Humana's prescription drug contract also earned a 4.5-star rating, contributing to its overall quality standing.

πŸ“… Annual Medicare enrollment opens October 15, 2026, with new coverage taking effect on January 1, 2027.

🩺 Humana facilitated 534,000 additional preventive visits and 663,000 more completed care opportunities compared to the previous year.

🦷 Screening efforts identified 600 previously undetected breast cancers and 17,000 cases of eye disease among diabetic patients.

πŸ’° Higher star ratings increase Humana's eligibility for quality-based bonus payments from the federal government.

πŸ“Š JPMorgan analysts had expected between 60% and 70% of members to be in four-star plans, but Humana significantly exceeded this expectation.

Bullish Signals
  • Humana stock surged approximately 15% in premarket trading following the announcement of improved Medicare Advantage Star Ratings for 2027.
  • The company achieved a major milestone with 95% of its Medicare Advantage members enrolled in four-star or higher plans, compared to only 20% last year.
  • Humana secured 4.5-star ratings for six contracts and four-star ratings for twelve others, exceeding the previous year's total by eleven contracts.
  • The insurer's prescription drug contract earned a 4.5-star rating, reinforcing its strong performance across different plan types.
  • Humana reported 534,000 additional preventive visits and 663,000 more completed care opportunities than the prior year, demonstrating operational excellence.
  • Specific outreach efforts successfully identified 600 previously undetected breast cancers and 17,000 cases of eye disease among diabetic patients through screenings.
  • The improved star ratings directly enhance Humana's eligibility for quality-based bonus payments from the federal government, boosting potential revenue.
Full Analysis
Humana Inc. (NYSE: HUM) saw its stock surge approximately 15% in premarket trading following a significant improvement in its Medicare Advantage Star Ratings for the upcoming 2027 plan year. The company reported that 95% of its Medicare Advantage members are now enrolled in plans rated four stars or higher, a substantial increase from the previous year where only 20% of members held such ratings. Specifically, Humana secured 4.5-star ratings for six contracts and four-star ratings for twelve others, exceeding last year's total by eleven contracts. Additionally, its prescription drug contract achieved a 4.5-star rating. These high scores are critical as they determine eligibility for quality-based bonus payments from the federal government, directly impacting the company's revenue potential. The improved performance is driven by robust preventive care metrics, including 534,000 additional completed preventive visits and 663,000 more care opportunities compared to the prior year. Humana highlighted specific successes in screening programs, such as identifying 600 previously undetected breast cancers through overdue mammograms and detecting 17,000 cases of eye disease among diabetic patients, demonstrating tangible value to its member base.